X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1846) 1846
Book Review (509) 509
Publication (147) 147
Book Chapter (11) 11
Newsletter (5) 5
Conference Proceeding (3) 3
Book / eBook (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1540) 1540
humans (1477) 1477
male (1403) 1403
prostate cancer (1070) 1070
oncology (1054) 1054
docetaxel (987) 987
mitoxantrone (895) 895
chemotherapy (859) 859
mitoxantrone plus prednisone (800) 800
prostatic neoplasms - drug therapy (719) 719
aged (703) 703
middle aged (648) 648
prednisone (558) 558
cancer (549) 549
urology & nephrology (527) 527
antineoplastic combined chemotherapy protocols - therapeutic use (485) 485
treatment outcome (481) 481
prostatic neoplasms - pathology (415) 415
aged, 80 and over (403) 403
metastasis (379) 379
care and treatment (366) 366
survival (365) 365
antineoplastic agents - therapeutic use (363) 363
taxoids - administration & dosage (297) 297
taxoids - therapeutic use (293) 293
prostatic neoplasms, castration-resistant - drug therapy (259) 259
prostate-specific antigen - blood (258) 258
therapy (258) 258
men (252) 252
research (243) 243
abiraterone acetate (220) 220
increased survival (219) 219
trial (216) 216
antineoplastic combined chemotherapy protocols - adverse effects (213) 213
drug therapy (210) 210
adult (207) 207
disease-free survival (206) 206
mitoxantrone - administration & dosage (203) 203
prognosis (198) 198
survival analysis (196) 196
prostatic neoplasms - mortality (190) 190
urology (189) 189
estramustine (184) 184
phase-ii trial (184) 184
neoplasm metastasis (183) 183
carcinoma (182) 182
drug resistance, neoplasm (182) 182
prostatic neoplasms - therapy (180) 180
prednisone - administration & dosage (178) 178
prostatic neoplasms, castration-resistant - pathology (177) 177
medicine & public health (175) 175
castration-resistant prostate cancer (172) 172
clinical trials (172) 172
enzalutamide (172) 172
female (171) 171
pharmacology & pharmacy (171) 171
androgen antagonists - therapeutic use (170) 170
double-blind (170) 170
abiraterone (168) 168
orchiectomy (168) 168
castration (166) 166
cabazitaxel (164) 164
disease progression (164) 164
retrospective studies (159) 159
analysis (151) 151
hematology, oncology and palliative medicine (150) 150
prostate (150) 150
survival rate (146) 146
cancer therapies (143) 143
clinical-trials (143) 143
health aspects (140) 140
bone neoplasms - secondary (139) 139
immunotherapy (137) 137
phase-ii (136) 136
drug administration schedule (134) 134
radical prostatectomy (132) 132
quality of life (130) 130
animals (126) 126
antineoplastic agents - administration & dosage (126) 126
antineoplastic agents, hormonal - therapeutic use (123) 123
antineoplastic combined chemotherapy protocols - administration & dosage (123) 123
hematology (123) 123
abridged index medicus (121) 121
antineoplastic agents (121) 121
clinical trials as topic (121) 121
prostate-specific antigen (121) 121
adenocarcinoma - drug therapy (120) 120
plus prednisone (116) 116
neoplasm staging (115) 115
development and progression (114) 114
prostatic neoplasms - blood (114) 114
prostatic neoplasms - surgery (111) 111
taxoids - adverse effects (111) 111
androgens (109) 109
risk factors (109) 109
oncology, experimental (107) 107
antimitotic agents (106) 106
antitumor-activity (105) 105
prostatic neoplasms - metabolism (105) 105
randomized controlled trials as topic (105) 105
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1777) 1777
German (33) 33
French (32) 32
Spanish (12) 12
Polish (2) 2
Chinese (1) 1
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2004, Volume 351, Issue 15, pp. 1502 - 1512
Men with metastatic hormone-refractory prostate cancer have a life expectancy of only about a year. More than 1000 such men were randomly assigned to receive... 
MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | PLACEBO | THERAPY | PAIN | MEN | DOUBLE-BLIND | RANDOMIZED-TRIAL | QUALITY-OF-LIFE | LOW-DOSE HYDROCORTISONE | ESTRAMUSTINE | Prednisone - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Adenocarcinoma - drug therapy | Prostatic Neoplasms - mortality | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Quality of Life | Aged | Mitoxantrone - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Adenocarcinoma - mortality | Care and treatment | Prednisone | Dosage and administration | Prostate cancer | Docetaxel | Comparative studies | Medical treatment | Men | Index Medicus | Abridged Index Medicus | Adenocarcinoma/drug therapy/mortality | Comparative Study | Medical and Health Sciences | Medicin och hälsovetenskap | Mitoxantrone/administration & dosage/adverse effects | Onkologi | Oncology | Klinisk medicin | MEDICINE | Drug Resistance; Neoplasm | Taxoids/administration & dosage/adverse effects | Prostatic Neoplasms/drug therapy/mortality | Surgery | Aged; 80 and over | Research Support; Non-U.S. Gov't | Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use | Prednisone/administration & dosage | Kirurgi | Clinical Medicine | MEDICIN | Cancer and Oncology | Cancer och onkologi
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1147 - 1154
Summary Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy... 
Internal Medicine | EVERY 3 WEEKS | MEDICINE, GENERAL & INTERNAL | PAIN | SOLID TUMORS | END-POINTS | TAXANE | CHEMOTHERAPY | ESTRAMUSTINE | Prostatic Neoplasms - metabolism | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms - immunology | Antineoplastic Agents, Hormonal - therapeutic use | Treatment Failure | Neutropenia - chemically induced | Mitoxantrone - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Prostatic Neoplasms - pathology | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Biomarkers, Tumor - blood | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Infusions, Intravenous | Pain Measurement | Dosage and administration | Prednisone | Research | Drug therapy | Prostate cancer | Mitoxantrone hydrochloride | Studies | Chemotherapy | Medical imaging | Physicians | Family medical history | Radiation therapy | Clinical medicine | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 338 - 348
Summary Background Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated... 
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | ONCOLOGY | MEN | END-POINTS | ABIRATERONE ACETATE | INCREASED SURVIVAL | DOCETAXEL | ENZALUTAMIDE | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | North America | Prostatic Neoplasms, Castration-Resistant - pathology | Time Factors | Prednisone - administration & dosage | Double-Blind Method | Europe | Risk Factors | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Adenocarcinoma - secondary | Disease Progression | New Zealand | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Naphthalenes - administration & dosage | Intention to Treat Analysis | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Australia | Adenocarcinoma - mortality | Medical colleges | Care and treatment | Chemotherapy | Corticosteroids | Cytochrome P-450 | Clinical trials | Prednisone | Metastasis | Prostate cancer | Cancer | Steroids | Index Medicus
Journal Article
Journal Article
Oncology, ISSN 0030-2414, 04/2005, Volume 68, Issue 1, pp. 2 - 9
Journal Article